Skip to main content
. Author manuscript; available in PMC: 2020 May 15.
Published in final edited form as: Clin Cancer Res. 2019 Aug 27;25(22):6801–6814. doi: 10.1158/1078-0432.CCR-19-0405

Figure 1. Injection of Delta-24-RGDOX into the primary s.c. melanoma inhibits distant untreated s.c. melanoma and induces immune memory.

Figure 1.

A, A cartoon depiction of the treatment scheme for the schedule (left) and position of implantation and viral injection (right). s.c.: subcutaneously; i.t.: intratumorally. B, Representative bioluminescent images of mice treated with PBS or Delta-24-RGDOX at indicated time points. C, Spider plots of the tumor bioluminescence in the mice from the indicated treatment groups. D, Survival plots of the treatment groups (n = 9). E, Survival plots Delta-24-RGDOX treatment survivors after being first re-challenged with B16F10 Red-FLuc (left panel, n = 4) and then CMT64 (right panel, n = 4) cells. D24-RGDOX: Delta-24-RGDOX; NS: not significant (P ≥ 0.05); *P < 0.01, log-rank test.